8:30 AM Introduction — Dr Love

MODULE 1 Multiple Myeloma, Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia — Drs Lonial and Zelenetz

8:35 AM Dr Lonial — Optimizing front-line therapy for patients with newly diagnosed multiple myeloma

Publications/presentations to be reviewed*:

Cavo M et al. Bortezomib (Velcade)-thalidomide-dexamethasone vs thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. Proc ASH 2007;Abstract 73.

Rajkumar SV et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASH 2007;Abstract 74.

Richardson P et al. Lenalidomide, bortezomib, and dexamethasone as front-line therapy for patients with multiple myeloma: Preliminary results of a phase 1/2 study. Proc ASH 2007;Abstract 187.

8:50 AM Case presentations from the practice of Dr Lonial

9:10 AM Dr Zelenetz — New agents and treatment strategies in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia

Publications/presentations to be reviewed:

Goy A et al. Durable responses with bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter PINNACLE study. Proc ASH 2007;Abstract 125.

Morrison VA et al. Maintenance rituximab compared to observation after R-CHOP or CHOP in older patients with diffuse large B-cell lymphoma: An Intergroup E4494/C9793 update. Proc ASCO 2007;Abstract 8011.

Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas — First interim results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Proc ASH 2007;Abstract 385.

Pfreundschuh M et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Proc ASCO 2008;Abstract 8508.

Czuczman MS et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Proc ASCO 2008;Abstract 8509.

Ferrajoli A et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7. Abstract

Knauf WU et al. Bendamustine versus chlorambucil in treatment-naïve patients with B-cell chronic lymphocytic leukemia: Results of an international Phase III study. Proc ASH 2007;Abstract 2043.

9:25 AM Case presentations from the practice of Dr Zelenetz

9:45 AM Q&A session with Drs Lonial and Zelenetz

10:15 AM Break

MODULE 2 Breast and Genitourinary Cancer — Drs Burstein and Oh

10:30 AM Dr Burstein — Implications of new research information on breast cancer clinical practice in 2008

Publications/presentations to be reviewed:

Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.

Gray RG et al. aTTom (adjuvant Tamoxifen — To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive or ER untested breast cancer — Preliminary results. Proc ASCO 2008;Abstract 513.

Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53. Abstract

Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. Proc ASCO 2008;Abstract LBA1011.

O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

10:45 AM Case presentations from the practice of Dr Burstein

11:05 AM Dr Oh — Recent advances in the management of metastatic renal cell carcinoma and advanced prostate cancer

Publications/presentations to be reviewed:

Escudier BJ et al. Update on AVOREN trial in metastatic renal cell carcinoma: Efficacy and safety in subgroups of patients and pharmacokinetic analysis. Proc ASCO 2008;Abstract 5025.

Ferretti G. Temsirolimus for advanced renal-cell carcinoma. N Engl J Med 2007;357(10):1050. Abstract

Whorf RC et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma. Proc ASCO 2008;Abstract 5010.

Figg WD et al. Randomized phase III trial of thalidomide or placebo for nonmetastatic PSA recurrent prostate cancer treated with intermittent therapy. Proc ASCO 2008;Abstract 5016.

De Bono JS et al. Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer. Proc ASCO 2008;Abstract 5005.

Dawson N et al. Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: Results of a phase II trial. Genitourinary Cancers Symposium 2008;Abstract 7.

11:20 AM Case presentations from the practice of Dr Oh

11:40 AM Q&A session with Drs Burstein and Oh

12:10 PM Lunch

MODULE 3 Colorectal and Lung Cancer — Drs Lynch and Fuchs

1:05 PM Dr Lynch — Optimal treatment algorithms for the management of Stage IV non-small cell lung cancer

Publications/presentations to be reviewed:

Pirker R et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer. Proc ASCO 2008;Abstract 3.

Douillard J-Y et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). Proc ASCO 2008;Abstract 8001.

Ciuleanu TE et al. Maintenance pemetrexed plus best supportive care versus placebo plus BSC: A phase III study. Proc ASCO 2008;Abstract 8011.

Akerley WL et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. Proc ASCO 2008;Abstract 8043.

1:20 PM Case presentations from the practice of Dr Lynch

1:40 PM Dr Fuchs — Emerging research information on colorectal cancer management

Publications/presentations to be reviewed:

Van Cutsem E et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Proc ASCO 2008;Abstract 2.

Allegra CJ et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil/sleucovorin and oxaliplatin (mFOLFOX6) with or without bevacizumab in the adjuvant treatment of patients with stage II/III colon cancer. Proc ASCO 2008;Abstract 4006.

Nikcevich DA et al. Effect of intravenous calcium and magnesium on oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. Proc ASCO 2008;Abstract 4009.

Grothey A et al. Intermittent oxaliplatin administration and time-to-treatment-failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial. Proc ASCO 2008;Abstract 4010.

1:55 PM Case presentations from the practice of Dr Fuchs

2:15 PM Q&A session with Drs Lynch and Fuchs

2:45 PM Break

3:00 PM Dr Love — Current patterns of care in medical oncology: How are emerging clinical research data incorporated into practice?

3:30 PM Close

* Additional publications not available at the time of this mailing may also be included for presentation

This event is supported by educational grants from AstraZeneca Pharmaceuticals LP,
Bristol-Myers Squibb Company, Celgene Coporation, Genentech BioOncology, ImClone Systems Incorporated, Millennium Pharmaceuticals — The Takeda Oncology Company, Sanofi-Aventis and Wyeth.